返回ChemicalBook首页>CAS数据库列表>18080-67-6

18080-67-6

中文名称 1,4-二氧代-2,3-二溴甲基喹啉
英文名称 2,3-BIS(BROMOMETHYL)QUINOXALINE 1,4-DIOXIDE
CAS 18080-67-6
分子式 C10H8Br2N2O2
分子量 347.99
MOL 文件 18080-67-6.mol
更新日期 2024/08/26 15:20:08
18080-67-6 结构式 18080-67-6 结构式

基本信息

中文别名
1,4-二氧代-2,3-二溴甲基喹啉
英文别名
Conoidin A
2,3-BIS(BROMOMETHYL)QUINOXALINE 1,4-DIOXIDE
Quinoxaline, 2,3-bis(bromomethyl)-, 1,4-dioxide
2,3-bis(broMoMethyl)-1-oxoquinoxalin-1-iuM-4(1H)-olate
所属类别
医药中间体:喹啉类化合物

物理化学性质

熔点180-190 °C (decomp)
沸点512.3±60.0 °C(Predicted)
密度1.95±0.1 g/cm3(Predicted)
溶解度DMF: 25 mg/ml; DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml; DMSO: 20 mg/ml
酸度系数(pKa)1.91±0.30(Predicted)
形态A crystalline solid
颜色White to yellow

安全数据

危险性描述H413
防范说明P273-P501
1,4-二氧代-2,3-二溴甲基喹啉价格(试剂级)
报价日期产品编号产品名称CAS号包装价格
2024/08/19HY-1160901,4-二氧代-2,3-二溴甲基喹啉
Conoidin A
18080-67-625mg500元
2024/08/19HY-1160901,4-二氧代-2,3-二溴甲基喹啉
Conoidin A
18080-67-610mM * 1mLin DMSO550元
2024/08/19HY-1160901,4-二氧代-2,3-二溴甲基喹啉
Conoidin A
18080-67-6100mg1000元

常见问题列表

生物活性
Conoidin A 是刚地弓形虫过氧化物酶 II (TgPrxII) 的细胞通透性抑制剂,有杀线虫的特性。Conoidin A 共价结合 TgPrxII 的过氧化物催化位点 Cys47,不可逆地抑制其过氧化物活性,IC50 为 23 µM。Conoidin A 也抑制哺乳动物 PrxI 和 PrxII (但不抑制 PrxIII) 的氧化。Conoidin A 具有抗氧化、神经保护作用,并且可用于缺血性心脏病的研究。
靶点

IC50: 23 µM ( T. gondii enzyme peroxiredoxin II (TgPrxII))

体外研究

Peroxiredoxins are a widely conserved family of enzymes that function in antioxidant defense and signal transduction. And the changes in PrxII expression are associated with a variety of human diseases, including cancer.Conoidin A binds to the peroxidatic cysteine of TgPrxII, inhibiting its enzymatic activity in vitro. Conoidin A also shown to alkylate or crosslink catalytic cysteines of wild type AcePrx-1 in Ancylostoma ceylanicum and human PrxII and PrxIV with similar efficiency. But it is ineffective to mitochondrial hPrxIII.Conoidin A (5 µM) can inhibit the glucose oxidase-mediated hyperoxidation of mammalian peroxiredoxin I and II.

体内研究

Conoidin A (intraperitoneal injection; 5 mg/kg; for three successive days before MI/R injury) blocks the effect of Luteolin (HY-N0162) on the ST‐segment elevation. Furthermore, an increase in the infarct size presented of the MI/R group can be reduced by Luteolin. But pre‐treatment with conoidin A abolishs the effect of Luteolin. Pre‐treatment with conoidin A also prevents Luteolin-reduced activities of CK‐MB, AST and LDH in vivo .

Animal Model: Rat myocardial I/R model
Dosage: 5 mg/kg
Administration: Intraperitoneal injection; 5 mg/kg; for three successive days before MI/R injury
Result: Significantly reversed the antioxidative effect of Luteolin. Impaired the protective effects of luteolin.
"18080-67-6" 相关产品信息
1451-82-7 2163-42-0 1066-42-8